Granulomatosis de Wegener
| Agente | Año | Tipo de estudio | Pacientes (n) | TR (n) | Casos adversos | Recaída | Muertes |
|---|---|---|---|---|---|---|---|
| INFLIXIMAB | 2002 |
C |
7 |
7 |
1 |
0 |
0 |
2002 |
C |
6 |
5 |
1 |
0 |
0 |
|
2004 |
C |
19 |
17 |
7 |
5 |
0 |
|
2006 |
C |
6 |
0 |
0 |
0 |
0 |
|
| Total | 38 |
29 |
9 |
5 |
0 |
||
| % | 76,315789 |
23,6842105 |
|||||
| INFLIXIMAB | 2004 |
D |
1 |
1 |
0 |
0 |
0 |
2005 |
D |
1 |
1 |
0 |
0 |
0 |
|
2006 |
D |
1 |
1 |
0 |
0 |
0 |
|
2006 |
D |
1 |
1 |
0 |
0 |
0 |
|
| Total | 4 |
4 |
0 |
0 |
0 |
||
| % | 100 |
0 |
|||||
| ETANERCEPT | 2005 |
A |
89 |
62 |
21 |
51 |
2 |
| Total | 89 |
62 |
21 |
51 |
2 |
||
| RITUXIMAB | 2005 |
C |
7 |
7 |
1 |
2 |
0 |
2006 |
C |
10 |
10 |
7 |
1 |
0 |
|
2006 |
C |
8 |
2 |
0 |
0 |
0 |
|
2006 |
C |
10 |
10 |
1 |
3 |
0 |
|
2007 |
C |
8 |
6 |
1 |
1 |
0 |
|
2007 |
C |
6 |
6 |
3 |
1 |
0 |
|
| Total | 49 |
41 |
13 |
8 |
0 |
||
| % | 83,673469 |
26,5306122 |
|||||
| RITUXIMAB | 2001 |
D |
1 |
1 |
1 |
1 |
0 |
2004 |
D |
1 |
1 |
0 |
0 |
0 |
|
2005 |
D |
3 |
3 |
0 |
3 |
0 |
|
2005 |
D |
1 |
1 |
0 |
0 |
0 |
|
2005 |
D |
1 |
1 |
0 |
1 |
0 |
|
2005 |
D |
1 |
1 |
0 |
0 |
0 |
|
2005 |
D |
1 |
1 |
0 |
0 |
0 |
|
2005 |
D |
1 |
1 |
0 |
0 |
0 |
|
2006 |
D |
1 |
1 |
0 |
0 |
0 |
|
2007 |
D |
1 |
1 |
0 |
0 |
0 |
|
2007 |
D |
2 |
2 |
0 |
1 |
0 |
|
2007 |
D |
1 |
1 |
0 |
0 |
0 |
|
2007 |
D |
1 |
1 |
0 |
0 |
0 |
|
2006 |
D |
1 |
0 |
1 |
0 |
0 |
|
2007 |
D |
1 |
1 |
0 |
0 |
0 |
|
2007 |
D |
1 |
1 |
0 |
0 |
0 |
|
| Total | 19 |
18 |
2 |
6 |
0 |
||
| % | 94,736842 |
10,5263158 |